about
Identification of C-2 hydroxyethyl imidazopyrrolopyridines as potent JAK1 inhibitors with favorable physicochemical properties and high selectivity over JAK2Discovery and optimization of C-2 methyl imidazopyrrolopyridines as potent and orally bioavailable JAK1 inhibitors with selectivity over JAK2Identification of imidazo-pyrrolopyridines as novel and potent JAK1 inhibitorsStructure-based discovery of C-2 substituted imidazo-pyrrolopyridine JAK1 inhibitors with improved selectivity over JAK2Structure-based identification of ureas as novel nicotinamide phosphoribosyltransferase (Nampt) inhibitorsNovel triazolo-pyrrolopyridines as inhibitors of Janus kinase 1Discovery of potent and efficacious urea-containing nicotinamide phosphoribosyltransferase (NAMPT) inhibitors with reduced CYP2C9 inhibition propertiesIdentification of 2,3-dihydro-1H-pyrrolo[3,4-c]pyridine-derived ureas as potent inhibitors of human nicotinamide phosphoribosyltransferase (NAMPT)Identification of amides derived from 1H-pyrazolo[3,4-b]pyridine-5-carboxylic acid as potent inhibitors of human nicotinamide phosphoribosyltransferase (NAMPT)Design and evaluation of novel 8-oxo-pyridopyrimidine Jak1/2 inhibitorsDiscovery of potent and efficacious cyanoguanidine-containing nicotinamide phosphoribosyltransferase (Nampt) inhibitorsFragment-based design of 3-aminopyridine-derived amides as potent inhibitors of human nicotinamide phosphoribosyltransferase (NAMPT)Structural and biochemical analyses of the catalysis and potency impact of inhibitor phosphoribosylation by human nicotinamide phosphoribosyltransferaseIdentification of nicotinamide phosphoribosyltransferase (NAMPT) inhibitors with no evidence of CYP3A4 time-dependent inhibition and improved aqueous solubilityMinimizing CYP2C9 Inhibition of Exposed-Pyridine NAMPT (Nicotinamide Phosphoribosyltransferase) Inhibitors
P50
Q27644279-EDAFC916-C013-480F-82E4-36352A065314Q27644486-46E3582B-85D5-4F58-9615-EB89CE48825CQ27679110-36B05177-2D99-49A6-B5F0-216EE844A98FQ27683098-B0C58B79-1AD3-4225-A919-7EB7944B5D2AQ27684477-E8319F15-741B-4208-93FC-E181CBB6C674Q27684544-9E7D76EF-911D-46D7-8724-39E14BDFA293Q27684607-6057F76D-3086-43EB-ACCE-71363E87EE93Q27685311-AFA46F4A-DDF2-417C-B059-E83B41990550Q27685484-9915DC0F-ACB9-46FB-8A74-4434178C0DA8Q27686691-8733E9C8-436C-41A6-8E68-6A293827B936Q27687697-F536B356-E7C0-4AB1-8ED4-6B83EDF44A1CQ27688912-4709F9E2-DC20-402E-BB04-7CDA4D7D966BQ27690154-FC90026F-0E80-4361-AF55-3E934EFBB971Q27697281-A757FFE1-09DC-4889-8BEE-71321103900FQ27727713-63659EBB-E21F-4DCD-9A49-D5252B715171
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Mark Zak
@ast
Mark Zak
@en
Mark Zak
@es
Mark Zak
@nl
Mark Zak
@sl
type
label
Mark Zak
@ast
Mark Zak
@en
Mark Zak
@es
Mark Zak
@nl
Mark Zak
@sl
prefLabel
Mark Zak
@ast
Mark Zak
@en
Mark Zak
@es
Mark Zak
@nl
Mark Zak
@sl